Drug intelligence / Profile preview

Chikungunya VSV-based vaccine (Auro Vaccines)

Development stage: Approved
Lead developer: Auro Vaccines
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Chikungunya VSV-based vaccine is an experimental viral vector vaccine developed by Auro Vaccines (utilizing technology acquired from Profectus BioSciences) for the prevention of Chikungunya fever. It is built on the proprietary VesiculoVax™ platform, which uses an attenuated recombinant Vesicular Stomatitis Virus (rVSV) as a vector to deliver and express Chikungunya virus (CHIKV) antigens, specifically the envelope polyprotein (E3-E2-6K-E1). This platform is designed to induce rapid and robust cellular and humoral immune responses. While Aurobindo Pharma (Auro's parent company) has a distribution agreement for Valneva's FDA-approved live-attenuated vaccine, Ixchiq (VLA1553), this VSV-based candidate remains a distinct asset in Auro's internal development pipeline.

Other names: VesiculoVax Chikungunya vaccineAuro Vaccines Chikungunya vaccine

Targets

Chikungunya virus envelope polyprotein

Beyond the preview

Go deeper on Chikungunya VSV-based vaccine (Auro Vaccines).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chikungunya VSV-based vaccine (Auro Vaccines).

Explore the full profile